BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:23 PM
 | 
Aug 05, 2008
 |  BC Extra  |  Clinical News

Heplisav meets HBV endpoint

Dynavax (NASDAQ:DVAX) and Merck (NYSE:MRK) said top-line data from the Phase III PHAST trial in 2,427 patients showed that Heplisav met the primary endpoint of a seroprotective immune response against HBV surface antigen (HBsAg) vs. Engerix-B...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >